Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00166-1 ◽

2021 ◽

Author(s):

Yosuke Kawashima ◽

Tatsuro Fukuhara ◽

Haruhiro Saito ◽

Naoki Furuya ◽

Kana Watanabe ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Egfr Mutant ◽

Overall Survival Analysis

Download Full-text

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00134-x ◽

2021 ◽

Author(s):

Jianxing He ◽

Chunxia Su ◽

Wenhua Liang ◽

Shidong Xu ◽

Lin Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adjuvant Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Egfr Mutant

Download Full-text

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Cited By ~ 1

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1039-0 ◽

2016 ◽

Vol 22 (1) ◽

pp. 70-78 ◽

Cited By ~ 2

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30035-x ◽

2019 ◽

Vol 20 (5) ◽

pp. 625-635 ◽

Cited By ~ 107

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Interim Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase

Download Full-text

Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(17)30262-x ◽

2017 ◽

Vol 5 (9) ◽

pp. 707-716 ◽

Cited By ~ 69

Author(s):

Jin-Ji Yang ◽

Caicun Zhou ◽

Yisheng Huang ◽

Jifeng Feng ◽

Sun Lu ◽

...

Keyword(s):

Controlled Trial ◽

Small Cell ◽

Small Cell Lung ◽

Whole Brain Irradiation ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Brain Irradiation ◽

Egfr Mutant ◽

Randomised Controlled

Download Full-text

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30365-9 ◽

2020 ◽

Author(s):

Caicun Zhou ◽

Gongyan Chen ◽

Yunchao Huang ◽

Jianying Zhou ◽

LiZhu Lin ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Archivos de Bronconeumología (English Edition) ◽

10.1016/j.arbr.2017.07.016 ◽

2018 ◽

Vol 54 (1) ◽

pp. 10-17

Author(s):

Filipa Aguiar ◽

Gabriela Fernandes ◽

Henrique Queiroga ◽

José Carlos Machado ◽

Luís Cirnes ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutated ◽

Overall Survival Analysis

Download Full-text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Download Full-text